---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-060452"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:11:07.525591+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Athira Pharma Q1 2024 net loss $26.3M ($0.69/share); cash $122.1M; LIFT-AD data H2 2024

## Summary
- Net loss of $26.3M ($0.69/share) vs $27.8M ($0.73/share) in Q1 2023; operating cash burn $25.8M.
- Cash and investments $122.1M as of March 31, 2024, down from $147.4M at year-end 2023.
- LIFT-AD Phase 2/3 topline data for fosgonimeton in Alzheimer's expected H2 2024; enrollment complete.
- IND submitted for ATH-1105 (ALS); first-in-human study expected to start Q2 2024.
- Appointed Javier San Martin, M.D. as Chief Medical Officer in April 2024.

## SEC filing metadata
- accession: 0000950170-24-060452
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000095017024060452/0000950170-24-060452-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000095017024060452/atha-20240515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-060452
- JSON: https://secwatch.observer/filing/0000950170-24-060452.json
- Plain text: https://secwatch.observer/filing/0000950170-24-060452.txt

## Key facts
- Earnings Releases
  LeonaBio, Inc. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: On May 15, 2024, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1620463/000095017024060452/0000950170-24-060452-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.